Table 3

Clinical trials of clear cell carcinoma using molecular targeted therapy

Study title	Status	Conditions	Interventions	Phase	Target	ClinicalTrials.gov identifier
GOG-0268	Completed	Newly diagnosed stage III or IV OCCC	Temsirolimus, carboplatin, and paclitaxel	II	mTOR	NCT01196429
GOG-0254	Completed	Persistent or recurrent OCCC	Sunitinib	II	PDGFRs and VEGFRs	NCT00979992
ENMD-2076-OCC	Completed	Persistent or recurrent OCCC	ENMD-2076	II	AURKA, VEGFRs, FGFRs, Flt3, and c-kit	NCT01914510
NRG-GY001	Completed	Persistent or recurrent OCCC	Cabozantinib	II	MET, RET, VEGFR2, and AXL	NCT02315430
GOG-0283	Active, not recruiting	Persisent or recurrent OCCC or endometrial CCC	Dasatinib	II	bcr-abl, c-kit, and PDGF	NCT02059265
NiCCC	Recruiting	Persistent or recurrent OCCC and endometrial CCC	Nintendanib	II	FGFRs, PDGFRs, and VEGFRs	NCT02866370
MOCCA	Recruiting	Persistent or recurrent OCCC	Durvalumab	II	PD-L1	NCT03405454
BrUOG 354	Recruiting	Persistent or recurrent OCCC or extra-renal origin CCC	Nivolumab ± ipilimumab	II	PD-1, CTLA4	NCT03355976
NRG-GY016	Suspended	Persistent or recurrent OCCC	Pembrolozimab and epacadostat	II	PD-1 and IDO1	NCT03602586

AURKA, aurora kinase A; CCC, clear cell carcinoma; CTLA4, cytotoxic T-lymphocyte-associated protein 4; FGFR, fibroblast growth factor receptor; Flt3, FMS-like tyrosine kinase; IDO1, idoleamine 2,3-dioxygenase-1; MET, MET proto-oncogene, receptor tyrosine kinase; mTOR, mammalian target of rapamycin; OCCC, ovarian clear cell carcinoma; PD-1, programmed cell death 1; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed cell death 1 ligand; RET, RET proto-oncogene, receptor tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.